

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

Hu CD20 BUV805 2H7

RRID:AB_2870192

Type: Antibody

Proper Citation

BD Biosciences Cat# 612905, RRID:AB_2870192

Antibody Information

URL: http://antibodyregistry.org/AB_2870192

Proper Citation: BD Biosciences Cat# 612905, RRID:AB_2870192

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Hu CD20 BUV805 2H7

Description: This monoclonal targets CD20

Target Organism: Human, Cynomolgus, Baboon, Rhesus

Clone ID: 2H7

Antibody ID: AB_2870192

Vendor: BD Biosciences

Catalog Number: 612905

Alternative Catalog Numbers: 612906

Record Creation Time: 20250820T063825+0000

Record Last Update: 20250821T003547+0000

Ratings and Alerts

No rating or validation information has been found for Hu CD20 BUV805 2H7.

No alerts have been found for Hu CD20 BUV805 2H7.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hsiao CC, et al. (2025) Acquisition of residency programs by T cells entering the human brain. *Cell reports*, 44(7), 115960.

Johnston TS, et al. (2024) Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. *Immunity*.

Barber-Axthelm IM, et al. (2023) Phenotypic and functional characterization of pharmacologically expanded V γ 9V γ 2 T cells in pigtail macaques. *iScience*, 26(3), 106269.

Blomberg OS, et al. (2023) IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. *Cancer cell*, 41(1), 106.

Mantus G, et al. (2022) Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination. *Cell reports. Medicine*, 3(4), 100603.

Goel RR, et al. (2022) Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. *Cell*, 185(11), 1875.

Bergamaschi L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8⁺ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. *Immunity*, 54(6), 1257.

Parsons MS, et al. (2021) Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure. *EBioMedicine*, 70, 103518.

Poran A, et al. (2020) Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1. *Cell reports. Medicine*, 1(8), 100141.